scispace - formally typeset
D

Do Young Kim

Researcher at Yonsei University

Publications -  737
Citations -  18320

Do Young Kim is an academic researcher from Yonsei University. The author has contributed to research in topics: Hepatocellular carcinoma & Medicine. The author has an hindex of 58, co-authored 674 publications receiving 15091 citations. Previous affiliations of Do Young Kim include University of Ulsan & Fred Hutchinson Cancer Research Center.

Papers
More filters
Journal ArticleDOI

Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization

TL;DR: In this paper, the optimal number of target lesions for hepatocellular carcinoma (HCC) was investigated for the European Association for the Study of the Liver (EASL) and modified Response Evaluation Criteria in Solid Tumors (mRECIST) guidelines in predicting overall survival (OS).
Journal ArticleDOI

Monitoring the occurrence of genetically modified maize at a grain receiving port and along transportation routes in the Republic of Korea

TL;DR: Investigation of whether imported GM maize is released into the authors' environment during the transportation of grain in the Republic of Korea found most of the maize grains in the forage products were GM, and about 50% of the grains were germinated.
Journal ArticleDOI

Predictive factors for long-term survival in patients with clinically significant portal hypertension following resection of hepatocellular carcinoma.

TL;DR: Hepatic resection for hepatocellular carcinoma (HCC) is not currently recommended for patients with clinically significant portal hypertension (PHT), however, recent studies have shown similar post‐operative outcomes between patients with and without clinically significant PHT.
Journal Article

[Reappraisal of HBV genotypes and clinical significance in Koreans using MALDI-TOF mass spectrometry].

TL;DR: Analysis of HBV genotypes in a large population using a new technology, restriction fragment mass polymorphism (RFMP) using MALDI-TOF mass spectrometry, in a sensitive and specific manner concluded that genotype A seems to take a more benign clinical course than genotype C.